Manel Cascalló

Institut de Seguretat Pública de Catalunya — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index2.3kcitations84works0.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(78), Cancer Research and Treatments(46), CAR-T cell therapy research(32), Viral Infectious Diseases and Gene Expression in Insects(30), RNA Interference and Gene Delivery(16)

Publications84 total

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters
Human Gene Therapy·2025
A phase I dose-escalation study to assess the oncolytic virus VCN-01 safety and efficacy in refractory retinoblastoma patients.
Journal of Clinical Oncology·2025
VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.
Journal of Clinical Oncology·2024· 2 cited
Supplemental Figure 2 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Data from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Supplemental Figure 1 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplemental Figure 3 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Supplemental Figure 4 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Data from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Supplemental Figure 2 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Supplemental Figure 1 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Supplementary Figures S1-S3, Materials and Methods from Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
2023Open Access
Supplementary Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplemental Figure 4 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Supplemental Figure 3 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
2023Open Access
Data from Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
2023Open Access
Data from Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
2023Open Access
Supplementary Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Ramón Alemany(41), Alena Gros(13), Juan J. Rojas(10), Marta Giménez-Alejandre(10), Rafael Moreno(10), Gabriel Capellá(10), Sònia Guedan(7), Miriam Bazán‐Peregrino(7), Jordi Martínez‐Quintanilla(6), Ana Mato-Berciano(6), Cristina Fillat(6), Cristina Puig-Saus(6), Elena Mercadé(5), Ramón Salazar(5), Marta M. Alonso(5), Rocio García‐Carbonero(5), C. Blasco(5), Neus Bayó-Puxan(5), Adela Mazo(5), Joaquim Calbó(5)